@article{Al-biati_Ismail_Sahib_Kazaal_Al-Rubaie_2017, title={Effects of sildenafil on lipid profile and glycemic control in patients with type 2 diabetes mellitus and metabolic syndrome}, volume={3}, url={https://www.ijbcp.com/index.php/ijbcp/article/view/1185}, abstractNote={<p class="ABS"><span class="Bold">Background:</span> Insulin resistance impairs nitric oxide (NO) bioavailability; obesity promotes a state of metabolic syndrome and damages the vascular endothelium by altering lipid profile. Phosphodiesterase-5 (PDE-5) inhibitors restore NO signaling may improve metabolic parameters through a number of mechanisms. We hypothesized that daily administration of the PDE-5 inhibitor; sildenafil will improve fasting plasma glucose (FPG), triglyceride (TG) levels and body weight, in obese diabetic patients.</p><p class="ABS"><span class="Bold">Methods:</span> Totally, 25 obese diabetic male patients with metabolic syndrome treated with sildenafil 25 mg daily for 3 months. Body weight, FPG levels, and lipid profile were determined monthly.</p><p class="ABS"><span class="Bold">Results:</span> Treatment with sildenafil caused a reduction in fasting glucose levels, fasting TGs, cholesterol, low-density lipoprotein (LDL), very-LDL and increased high-density lipoprotein; body weight was significantly reduced.</p><p class="ABS"><span class="Bold">Conclusion:</span> We have provided the first evidence that sildenafil therapy improve glycemic control, lipid profile and body mass index in diabetic patients with metabolic syndrome.</p>}, number={6}, journal={International Journal of Basic & Clinical Pharmacology}, author={Al-biati, Haedar Abdulhafith and Ismail, Sajida Hussein and Sahib, Ahmed Salih and Kazaal, Faris Abdul Kareem and Al-Rubaie, Salim}, year={2017}, month={Jan.}, pages={1048–1051} }